Article: CONTINUATION: NHS refuses to fund the pill that offers relief to millions of hay fever sufferers ; THE CURE AND THE CATCH

fever season at its peak, millions of people with an allergy to grass pollen are sneezing, snuffling and rubbing itchy eyes. Hay fever affects about 20 per cent of the UK population - more than 10 million people - of whom up to one million are so badly affected it interferes with their lives.

The new treatment, Grazax, is the first oral vaccine for hay fever developed to tackle the underlying condition rather than the symptoms. Manufactured by a Danish company, and licensed in January, it contains small amounts of Timothy grass and is designed to "recondition" the immune system's response to pollen in people who do not respond to normal treatment.

According to a study released yesterday, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!